-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
ArticleMedicine Guanlan
Today, China's National Food and Drug Administration (NMPA) announced that the pregabalin sustained-release tablets declared by Hengrui Medicine have been approved for listing in China
Screenshot source: NMPA official website
Pregabalin is an analogue of the neurotransmitter γ-aminobutyric acid (GABA).
The original drug pregabalin has been approved for multiple indications worldwide, including diabetic peripheral neuropathy, post-herpetic neuralgia, fibromyalgia syndrome, neuralgia caused by spinal cord injury, and as an adjuvant therapy for adult patients Part of epileptic seizures and many other diseases
The dosage form declared by Hengrui Medicine is pregabalin sustained-release tablets
Reference materials:
[1] On September 28, 2021, the drug approval document pending information is released.